Three abstracts selected for the Best of ASCO program and Nine
chosen for clinical science symposiums and disease-specific oral sessions
American Society of Clinical Oncology (ASCO) has selected 60
abstracts authored by Sarah
Cannon Research Institute (SCRI) for presentation at the 2012
ASCO Annual Meeting, the premier educational and scientific oncology
conference, which takes place June 1-5 in Chicago.
The 60 presentations include nine abstracts in disease-specific oral
sessions, as well as 14 poster discussions; 28 general posters, and 9
Trials in Progress posters. A complete schedule of the presentations can
be found on sarahcannonresearch.com.
In addition, five abstracts were accepted for publication.
The studies selected include those focusing on the efficacy of new
treatments for breast, lung, and gastrointestinal cancers, as well as
blood cancers and carcinomas of unknown primary. Several trials
highlight the success of exploratory molecular assays in advancing
personalized medicine. The collaborative effort of physician researchers
across the SCRI community-based network in the United States and United
Kingdom enabled the completion of this innovative clinical research.
“ASCO’s selection of 60 abstracts authored by our investigators
demonstrates that we are fulfilling our mission of advancing therapies
for patients,” SCRI
CEO Dee Anna Smith said. “The record number of acceptances for SCRI
in 2012 is a tribute to the efforts of our entire team and especially to
the cancer patients who participated in these important clinical trials.”
Three studies were chosen for the Best of ASCO program, which condenses
highlights from ASCO’s Annual Meeting into a two-day program and
reflects research that is considered particularly relevant to the
practice of oncology.
Johanna C. Bendell, M.D., SCRI
Director, GI Cancer Research Program is the first author and presenter
of one of the Best of ASCO abstracts: a phase III randomized
double-blind placebo-controlled study of perifosine plus capecitabine
(P-CAP) vs. placebo plus capecitabine (CAP) in patients with refractory
metastatic colorectal cancer. In addition, Dr. Bendell will deliver the
lecture, “Colorectal Cancer Treatment is ready for Personalization, why
is it not being used?” at an educational session.
Two of the first-in-man Phase I studies led by the SCRI Drug Development
Program were chosen for oral presentations.